{
    "clinical_study": {
        "@rank": "16807", 
        "arm_group": {
            "arm_group_label": "BG00002 per label", 
            "description": "Study Drug"
        }, 
        "brief_summary": {
            "textblock": "The primary objective of the study is to evaluate the safety of BG00002 use in the pediatric\n      multiple sclerosis (MS) population."
        }, 
        "brief_title": "Safety and Efficacy in Pediatric MS Patients Prescribed Tysabri\u00ae", 
        "completion_date": {
            "#text": "September 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Multiple Sclerosis", 
        "condition_browse": {
            "mesh_term": [
                "Multiple Sclerosis", 
                "Sclerosis"
            ]
        }, 
        "detailed_description": {
            "textblock": "All available retrospective and prospective data from pediatric MS participants who have\n      received at least 1 dose of BG00002 before turning 18 years old and before 31 March 2015.\n      All available retrospective and prospective data from pediatric MS participants who have\n      received at least 1 dose of BG00002 before turning 18 years old and before 31 March 2015\n      will be used in this study.  Prospective data are defined as data to be collected in the\n      future, i.e., from new participants not included in the first data transfer or additional\n      data from existing participants that were not included in the first data transfer. Existing\n      biospecimen samples will be evaluated but not collected as part of this study."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Key Inclusion Criteria:\n\n          -  All available retrospective and prospective data from pediatric MS patients who have\n             received at least 1 dose of BG00002  before turning 18 years old and before 31 March\n             2015.\n\n          -  In addition, patients must be registered in TOUCH (US patients only), enrolled in a\n             Biogen Idec sponsored postmarketing observational study (e.g., TOP (NCT00493298) or\n             TYGRIS (NCT00477113,NCT00483847)), or in a country-specific TYSABRI\u00ae registry.\n\n          -  Adequate data received by Biogen Idec by 30 September 2015 will be used for this\n             meta-analysis including data collected after a patient may have turned 18 years old.\n\n        Key Exclusion Criteria:\n\n          -  Data received by Biogen Idec after 30 September 2015 will not be included in the\n             statistical analyses\n\n        NOTE: Other protocol-defined inclusion/exclusion Criteria May Apply"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "18 Years", 
            "minimum_age": "N/A", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Pediatric multiple sclerosis (MS) patients who have received at least 1 dose of BG0002\n        prior to the age of 18 years where the first dose was administered prior to 31 March 2015."
            }
        }, 
        "enrollment": {
            "#text": "400", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 1, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02137109", 
            "org_study_id": "101MS028"
        }, 
        "intervention": {
            "arm_group_label": "BG00002 per label", 
            "description": "As per local label specifications", 
            "intervention_name": "BG00002 (Natalizumab)", 
            "intervention_type": "Drug", 
            "other_name": "Tysabri\u00ae"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Pediatric", 
        "lastchanged_date": "May 9, 2014", 
        "number_of_groups": "1", 
        "official_title": "Meta-Analysis of the Safety and Efficacy of Natalizumab in Pediatric Patients With Multiple Sclerosis", 
        "overall_official": {
            "affiliation": "Biogen Idec", 
            "last_name": "Medical Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Enrolling by invitation", 
        "oversight_info": {
            "authority": "Sweden: Regional Ethical Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "September 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Incidence of all serious adverse events (SAEs)", 
            "safety_issue": "Yes", 
            "time_frame": "Up to 19 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02137109"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Biogen Idec", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Biogen Idec", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Observational Model: Case-Only", 
        "study_type": "Observational", 
        "verification_date": "May 2014"
    }
}